Poster presentation, P73

Official XXIst International Pigment Cell Conference website - 21-24 Sept 2011, Bordeaux - France | updated: September 04 2011

A Randomised Controlled Trial assessing the effectiveness of Minigrafting Vs ReCell in Stable Vitiligo: preliminary results

BACKGROUND: Non-cultured Epidermal Suspension (NCES) involves preparing a split thickness skin graft which is processed into an epidermal cell suspension with the ReCell device and transplanted onto dermabraded skin affected with vitiligo. The role of ReCell as a surgical treatment in vitiligo has been published as case reports and this study seeks to determine if repigmentation differs between NCES and minigrafting. METHODS: We are currently conducting a prospective intra-patient single centre randomised comparison trial for patients with chronic stable vitiligo. Participants have both minigrafting and NCES performed on randomised anatomically paired sites. Pre and post-procedure pictures of donor and recipient sites are used to evaluate the percentage of repigmentation which is assessed by an independent blinded investigator. RESULTS: The primary outcome of the trial is the percentage repigmentation at 12 months of NCES as compared with the conventional minigrafting. Secondary outcomes include percentage repigmentation at 3 and 6 months and cosmetic outcome of recipient and donor sites assessed by investigators and subjects. Interim results of 14 patients: ReCell was associated with 27% and 15% repigmentation at 3 and 12 months compared to 11% and 12% with minigrafting, respectively. Both subjects and investigators thought ReCell provided a better cosmetic outcome at the donor site but most subjects preferred the speckled pigmentation at recipient sites of the minigrafting. CONCLUSION: Our results require more power for statistical comparison but suggest a potential beneficial use of the ReCell device in the treatment of stable vitiligo.

Advertisement from our sponsor: